Blue Owl Capital Holdings »

Blueprint Medicines shares owned by Blue Owl Capital Holdings

Quarter-by-quarter ownership of Blueprint Medicines (BPMC) shares owned by Blue Owl Capital Holdings from 13F filings

Historical chart of Blue Owl Capital Holdings investment in Blueprint Medicines

Tip: Access up to 7 years of quarterly data

All positions including Blueprint Medicines held by Blue Owl Capital Holdings consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Blueprint Medicines by Blue Owl Capital Holdings

Quarter filed Position value Share count Share price at filing
2023-12-31 $6.6M 72k 92.24

More positions owned by Blue Owl Capital Holdings

Robinhood Mkts Com Cl A (HOOD)
Cullinan Oncology (CGEM)
Pliant Therapeutics (PLRX)
Engene Holdings (ENGN)
Tourmaline Bio (TRML)
Owl Rock Capital Corporation (OBDC)
Klaviyo Com Ser A (KVYO)
Larimar Therapeutics (LRMR)
Acelyrin (SLRN)
Evercommerce (EVCM)
Repare Therapeutics Ord (RPTX)
Ultragenyx Pharmaceutical (RARE)
Keros Therapeutics (KROS)
Inozyme Pharma (INZY)
Disc Medicine (IRON)

View all positions for Blue Owl Capital Holdings

Top funds holding Blueprint Medicines

BlackRock
Vanguard Group
T. Rowe Price Associates
FMR
Wellington Management Company
Rock Springs Capital Management
Pictet Asset Management Holding SA
William Blair Investment Management
Geode Capital Management
Alliancebernstein
Lord, Abbett & Co
Jpmorgan Chase & Co
Morgan Stanley
T. Rowe Price Investment Management
Woodline Partners

View all funds holding Blueprint Medicines